Trends in Antibody Drug Discovery for Cancer Therapy
Edited by Christian Klein Edited by John M. Lambert Series edited by János Fischer Series edited by Wayne E. Childers Series edited by David P. Rotella
Trends and challenges in one of the key areas of contemporary drug development – presented by industry professionals from leading pharmaceutical companies.
Part 1: THERAPEUTIC ANTIBODIES
(1) Introduction: Trends in antibody-based therapy of cancer
(2) PD-1 and PD-L1 checkpoint inhibitory antibodies
Part 2: BISPECIFIC ANTIBODIES
(3) T cell bispecific antibodies for B and plasma cell malignancies
(4) Case study: Glofitamab for Non-Hodgkin lymphoma
(5) Case study: Teclistamab and talquetamab for Non-Hodgkin lymphoma
(6) Bispecific antibodies blocking receptor tyrosine kinases
(7) Bispecific antibodies for solid tumors
(8) Immunocytokines
Part 3: ANTIBODY-DRUG CONJUGATES
(9) Next generation antibody drug conjugates
(10) Discovery and development of Enhertu (trastuzumab deruxtecan)
Part 4: NEXT-GENERATION BISPECIFIC ANTIBODIES
(11) Antibody PROTACs
- Edited by Christian Klein
- Edited by John M. Lambert
- Series edited by János Fischer
- Series edited by Wayne E. Childers
- Series edited by David P. Rotella
